potassium acetate + magnesium acetate + sodium chloride + dextrose

Potassium acetate + magnesium acetate + sodium chloride + dextrose is a sterile intravenous multiple-electrolyte and carbohydrate solution marketed as **Normosol-M and 5% Dextrose Injection** and described pharmacopeially as **Multiple Electrolytes and 5% Dextrose Injection Type 1**. It is a small-molecule electrolyte replacement and maintenance fluid formulation developed historically by Abbott and now associated with ICU Medical. The product is indicated for parenteral maintenance of routine daily fluid and electrolyte requirements with minimal caloric support from dextrose; magnesium is included to help reduce the risk of iatrogenic magnesium deficiency during prolonged parenteral therapy. Its therapeutic effect is not mediated by a discrete receptor target but by physiologic replacement of water, sodium, chloride, potassium, magnesium, acetate as a bicarbonate precursor, and dextrose as a source of carbohydrate calories.

Brand names

Normosol-M and 5% Dextrose Injection

Other names

potassium acetate + magnesium acetate + sodium chloride + dextroseMultiple Electrolytes and 5% Dextrose Injection Type 1dextrose monohydrate + sodium chloride + potassium acetate + magnesium acetate